XJXander Jacquemyn

Xander Jacquemyn

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Xander Jacquemyn has a total of 307 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Non-invasive estimation of right atrial pressure using magnetic resonance imaging: a development and validation study

    by Jef Van Den Eynde, Xander Jacquemyn, Hannah Van Belle, Youri Bekhuis, Anastasia Fambri, Tom Dresselaers, Alexander Van De Bruaene, Jan Bogaert

    Aims: Right atrial pressure (RAP) is a key determinant of right-sided heart function and guides diagnosis and management across a wide range of cardiovascular diseases. However, reliable non-invasive estimation remains difficult. We aimed to develop and validate a magnetic resonance imaging (MRI)-based model for predicting invasive RAP. Methods and results: This study included 181 adults who underwent clinically indicated MRI and right heart catheterization within 48 h between 2016 and 2025. The sample was split into a development (N = 125) and an independent held-out test-set cohort (N = 56) stratified by RAP category. Generalized additive models and systematic transformation screening were used to characterize non-linear predictor–outcome associations. Predictors were selected using pre-defined criteria (ΔAkaike information criterion ≥ 2, partial R2 ≥ 0.02, least absolute shrinkage and selection operator [LASSO] bootstrap inclusion ≥90%, physiological plausibility). The final model included inferior vena cava expiratory diameter (linear and quadratic terms), liver T1 relaxation time (linear and quadratic terms), right atrium area (linear), and body weight (linear). In the development cohort, performance was strong (adjusted R2 = 0.698; residual standard deviation 2.58 mmHg) and remained consistent across three internal validation approaches. Held-out test-set validation showed an R2 of 0.621, a root-mean-square error of 2.78 mmHg, a mean absolute error of 2.07 mmHg, and a concordance coefficient of 0.777. Calibration in the testing set was excellent (intercept + 0.18, slope = 0.92; integrated calibration index 0.65 mmHg). Discrimination for elevated RAP was high with area under the curves of 0.749 (>5 mmHg), 0.949 (>10 mmHg), and 0.965 (>15 mmHg). Conclusion: An MRI model incorporating abdominal venous and hepatic tissue biomarkers provides a clinically useful, well-calibrated approach for estimating invasive RAP.

  • Open Access

    Guidelines Versus Practice: Decision-Making and Outcomes of Transcatheter Aortic Valve Replacement in Patients Younger Than 65

    by Samuel Berhanu, Xander Jacquemyn, Irsa Hasan, Derek Serna-Gallegos, Dustin Kliner, Catalin Toma, Amber Makani, David West, Francis Ferdinand, Takuya Ogami


  • Open Access

    Primary Graft Dysfunction After Lung Transplantation: A Temporal Classification and Machine Learning Clustering

    by Balin Özsoy, Bieke Vercauteren, Jan Van Slambrouck, Cedric Vanluyten, Annalisa Barbarossa, Xin Jin, Dirk E. Van Raemdonck, Julia Dmitrieva, Anwar Khan, Xander Jacquemyn, et al.

    Background.: Primary graft dysfunction (PGD) is a major cause of morbidity and mortality after lung transplantation (LTx). PGD is graded at static time points, limiting insight into its temporal dynamics. Statistical risk-factor analysis may overlook the multifactorial complexity of PGD. Machine learning (ML) may address this but is constrained by small sample sizes. We aim to introduce a temporal PGD classification, perform ML-based clustering and overcome sample-size limitations by generating synthetic patient data. Methods.: A prospectively collected database of 794 LTx at University Hospitals Leuven (Belgium) from January 2012 to November 2023 was analyzed. Recipients were classified into 4 temporal PGD phenotypes: no, early, late, and persistent PGD. Unsupervised ensemble k -means clustering was used to group patients based on 30 clinical variables. To generate synthetic data, a Wasserstein Generative Adversarial Network with Gradient Penalty was trained. Results.: Six hundred ninety primary double LTx cases were included. Temporal PGD phenotypes showed significantly different 5-y survival (log-rank test: P <  0.001). K -means clustering revealed stable patient subgroups, with k =  5 and k =  9 identified as optimal cluster numbers. Key features affecting clustering included preoperative intensive care unit stay and postoperative chest x-rays. The synthetic data set preserved the correlation structure of the original data, and the combined data had similar clustering behavior, with optimal clustering at k =  5, k =  7, and k =  9. Conclusions.: This study demonstrates the potential of temporal PGD classification to better understand how the dynamic character of PGD affects survival. ML techniques, including unsupervised clustering and synthetic data generation, could be promising strategies to unravel complex interactions between clinical factors and overcome sample-size limitations.

  • Open Access

    Impact of Fenestration on Survival and Morbidity Following Fontan Surgery: A Time-to-Event Meta-Analysis of Reconstructed Kaplan–Meier Data

    by Rohit Ganduboina, Jef Van Den Eynde, Xander Jacquemyn, Omar Abdel Kerim, Sandeep Sainathan

    Introduction: The Fontan procedure revolutionized single-ventricle palliation by enabling passive pulmonary blood flow. Fenestration, an atrial-level shunt, reduces early postoperative complications by decompressing the circuit but causes systemic desaturation. Despite early benefits, fenestration's long-term impact on survival and morbidity remains uncertain. Methods: Reconstructed meta-analysis data from Kaplan-Meier curves of studies published up to December 25, 2024, following PRISMA guidelines was performed. Eligibility included Fontan patients with documented fenestration status and survival outcomes. Hazard ratios were estimated using Cox regression analysis with random effects, and proportional hazards violations were addressed with flexible parametric models. Results: Eight studies met our eligibility criteria and included 2,827 unmatched patients and 804 matched Fontan patients included in the Kaplan-Meier curves (1308 + 402 with fenestration and 1519 + 402 without fenestration). Fenestration was associated with significantly lower overall survival (HR 1.58; p = 0.006) and had increased thromboembolism risk. Subgroup analysis showed lower survival among patients without documented active fenestration closure. Regression findings imply that the effectiveness of fenestration is influenced by baseline hemodynamic severity. Conclusions: Fenestration in the Fontan procedure is associated with relatively lower long-term survival and increased thromboembolic risk. The benefits of fenestration may be greatest in patients with severe hemodynamic compromise, supporting a tailored rather than uniform approach to its application.

  • Prosthesis‐Patient Mismatch in All‐Comer Patients Undergoing Newer‐Generation Self‐Expanding Transcatheter Aortic Valve Replacement

    by Xander Jacquemyn, Takuya Ogami, Irsa Hasan, Dustin Kliner, Derek Serna‐Gallegos, Catalin Toma, Amber Makani, David West, Ibrahim Sultan

    Background: Prosthesis‐patient mismatch (PPM) after transcatheter aortic valve replacement (TAVR) may affect outcomes, but its incidence and impact with contemporary self‐expanding valves remain unclear. Aims: Evaluate the frequency, predictors, and long‐term outcomes of PPM in a real‐world TAVR population. Methods: We analyzed patients ≥ 18 years undergoing TAVR with current‐generation self‐expanding valves (Evolut FX/FX+, PRO/PRO+, Navitor, Navitor Vision) from a prospectively maintained institutional database (2017–2025). Predicted PPM was defined according to VARC‐3 criteria, with all‐cause mortality and heart failure hospitalization as the primary outcomes. Results: Among 2989 patients (median age 80 [75−85], 50.8% female) receiving Evolut (83.3%) or Navitor (16.7%) valves, PPM occurred in 5.0% (moderate 3.7%, severe 1.3%) and declined from 6.5% in 2017 to 2.7% in 2025 ( p = 0.002). Independent predictors of PPM included female sex (OR 2.04, 95% CI 1.06−3.99, p = 0.035) and valve‐in‐valve procedures (OR 9.60, 95% CI 3.82−25.64, p < 0.001), whereas use of the Navitor valve was associated with markedly lower odds (OR 0.07, 95% CI 0.00−0.32, p = 0.009). Patients with PPM demonstrated significantly higher post‐procedural transvalvular gradients and reduced aortic valve areas (both p < 0.001). PPM was not associated with adverse long‐term clinical outcomes, with no significant differences in 5‐year all‐cause mortality (HR 0.84, 95% CI 0.45−1.57, p = 0.592) or heart failure hospitalization (HR 1.22, 95% CI 0.84−1.77, p = 0.295). Conclusion: In this contemporary TAVR cohort, PPM was infrequent, and its incidence declined over time. Female sex and valve‐in‐valve procedures independently predicted PPM. Despite adverse hemodynamic profiles, PPM was not associated with early or long‐term adverse clinical outcomes.

  • Open Access

    Impact of Female Sex on Survival and Outcomes After Mitral Valve Surgery

    by Xander Jacquemyn, Rohit Ganduboina, Michel Pompeu Sá, Sara J. Pereira, Sabine Bleiziffer, Irsa Hasan, Takuya Ogami, Johannes Bonatti, Ibrahim Sultan

  • Open Access

    Valve‐in‐Valve Transcatheter Mitral Valve Replacement Versus Redo Surgical Mitral Valve Replacement: Meta‐Analysis of Early and Late Outcomes

    by Michel Pompeu Sá, Gabriel Neves, Leo Consoli, Asad Iqbal, Leonardo Dexheimer, David Abraham Batista da Hora, Thiago Camarotti, Xander Jacquemyn, Federico Napoli, Antonio Polanco, et al.

    Background: Bioprosthetic mitral valve degeneration is traditionally treated with redo surgical mitral valve replacement (redo‐SMVR), but valve‐in‐valve transcatheter mitral valve replacement (ViV‐TMVR) offers a less invasive alternative. Methods: Systematic review and meta‐analysis of studies comparing ViV‐TMVR and redo‐SMVR. PubMed/MEDLINE, EMBASE, Web of Science, and Cochrane databases (inception to September 2025) were searched. Meta‐analyses were conducted with random‐effects models to assess patient‐relevant outcomes; Kaplan–Meier‐derived time‐to‐event data were pooled to assess late outcomes. Results: Thirteen observational studies met our eligibility criteria, including 15 941 patients (ViV‐TMVR: 5465; redo‐SMVR: 10476). In comparison with redo‐SMVR, ViV‐TMVR was associated with lower risk of in‐hospital mortality (risk ratio [RR], 0.72 [95% CI, 0.57–0.90]; P =0.004), stroke (RR, 0.49 [95% CI, 0.29–0.83]; P =0.008), bleeding (RR, 0.43 [95% CI, 0.20–0.94]; P =0.035), acute kidney injury (RR, 0.57 [95% CI, 0.42–0.77]; P P P P =0.256); however, the landmark analysis revealed that ViV‐TMVR was associated with lower risk of death in the initial 6 months (HR, 0.69 [95% CI, 0.58–0.83]; P P <0.001). Conclusions: In patients amenable to ViV‐TMVR, this procedure shows a lower initial risk of death and complications, but higher mortality after 6 months in comparison with redo‐SMVR. These findings highlight the importance of striking a balance between upfront surgical risk and estimated life expectancy when selecting interventions.